Proceeds to advance PIPE-505 in hearing loss and additional neuroregenerative programs focused on synaptogenesis, remyelination and axonal repair
RBV Capital is a dedicated life sciences venture capital fund established in 2014 investing into innovative biomedical projects globally
At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets.
Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision.
We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies.
RBV Capital announces an exit from another project, returning the full investment amount to its limited partners
In 2017, RBV Capital acquired an equity stake in an innovative UK-based company developing an asset for treating symptoms of multiple sclerosis
Image Analysis Group (“IAG”).today announced a partnership in the field of ulcerative colitis (UC) histopathological image analysis with Takeda Pharmaceutical Company Limited (“Takeda”).